Abstract We conducted a meta-analysis of studies assessing adherence to highly active antiretroviral therapy (HAART) and a qualitative systematic review of factors associated with better HAART outcomes among HIV? drug users (DU). Thirty-eight studies were considered, which analyzed 14,960 patients (11,394 HIV? DU, 76.2%). Overall adherence (pooled percent of DU classified as adherent in each study) was 0.60 (95% CI: 0.52-0.68), similar to levels identified by studies conducted with HIV? patients who are not drug users. Time frame used to measure adherence was an independent predictor of interstudy heterogeneity. The systematic review identified better HAART outcomes among former DU, those with less severe psychiatric conditions, those receiving opioid substitution therapy and/or psychosocial support. Patients initiating HAART with lower viral load and higher CD4 counts, and those without co-infections also had better treatment outcomes. Our findings suggest that HIV? DU tend to be inappropriately assumed to be less adherent and unlikely to achieve desirable treatment outcomes, when compared to their non-DU cohort.
Introduction
Highly active antiretroviral therapy (HAART) has improved the health and quality of life of people living with HIV/AIDS (PLWHA) since its introduction in 1996/7. HAART reduces HIV viral load and increases CD4? cell levels, delaying progression to AIDS and reducing mortality (Egger et al. 2002) . Adherence to HAART is closely tied to HIV viral suppression and CD4 cell count response (Wood et al. 2003a (Wood et al. , 2004a and is a key predictor of antiretroviral success and survival (Hogg et al. 1998; Palella et al. 1998) .
Since reductions in HIV viral load may significantly reduce HIV transmission (Wood et al. 2008 ), HAART appears to be an important addition to the arsenal of HIV prevention strategies (Quinn et al. 2000) . However, since the advent of HAART, widening disparities in health outcomes among HIV-seropositive populations indicate the need to elucidate factors facilitating and impeding effective HAART use among disadvantaged or marginalized populations (Mills et al. 2006; Wood et al. 2003a) .
Previous studies have found that active drug users had sub-optimal adherence, resulting in poorer virologic and immunologic outcomes to HAART compared to former and non-drug users (Lucas et al. 2001 (Lucas et al. , 2002 Palepu et al. 2003a, b) . However, other studies have found that HIVpositive drug users who have access to drug abuse and mental health treatment (Malta et al. 2008) , and particularly former drug users who are abstinent, can attain the same levels of adherence found among PLWHA who have never used illicit drugs (Crystal et al. 2001) and can thus achieve similar survival rates compared to non-drug using populations (Wood et al. 2008) .
Drug users (DU) living with HIV/AIDS have been found to experience suboptimal access to HAART (Celentano et al. 1998; Bassetti et al. 1999; Strathdee et al. 1998) , and tend to initiate HAART at more advanced stages of infection (Celentano et al. 2001; Wang et al. 2004 ). This raises concern since injection drug use is a major vector for HIV transmission in seven of 10 regions around the world (Mathers et al. 2008; WHO/UNAIDS 2007) . Non-injecting DU are also at high risk for HIV infection due to high risk sexual behaviors (Inciardi and Surrat 2001; Latkin et al. 2001) . In recent years, the number of PLWHA increased substantially in east and central Asia, as well as in eastern Europe, where nearly two-thirds of HIV infections (62%) are attributed to injection drug use (Mathers et al. 2008) . In highly populated countries such as China and India, injection drug use is also a major contributor to local HIV/ AIDS epidemics (WHO/UNAIDS 2007; Mathers et al. 2008) .
Some providers prescribing HAART to DU have been concerned that clinical improvement may lead to high risk behaviors; patients learning that they have an undetectable viral load may believe he is no longer infectious and may start practicing unsafe sex (Atkinson et al. 2008; Vlahov and Celentano 2006) . Others have been concerned that suboptimal adherence may favor the emergence of viral resistance and the transmission of drug-resistant HIV strains (Vlahov and Celentano 2006; Wainberg and Friedland 1998; Wensing et al. 2005) .
The specific barriers that jeopardize HIV-positive drug users' adherence to HAART remain to be further elucidated. A former review paper by our group summarized the main barriers and facilitators of adherence among drug using populations (Malta et al. 2008) . In this meta-analysis, we synthesize the available scientific literature, presenting a pooled measurement of adherence among HIV-positive DU accounting for between-study heterogeneity. We also summarize factors associated with optimal HIV viral suppression and/or immunological reconstitution among the subset of studies that examined these treatment outcomes.
Methods
In planning our recent systematic review (Malta et al. 2008) and meta-analysis, we reviewed standard guidelines to conduct and report meta-analysis studies, which included the consolidated standards of reporting trials-CONSORT Moher et al. 2001 ), the quality of reporting of meta-analyses-QUOROM (Moher et al. 2000) , the meta-analysis of observational studies in epidemiology (MOOSE) group , and the transparent reporting of evaluations with nonrandomized designs-TREND (Des Jarlais et al. 2004) . Since many of the selected studies were observational studies rather than clinical trials, the MOOSE recommendations were used to conduct and report the meta-analysis, while the TREND checklist (Version 1.0) was used as a guide for data abstraction.
Search Strategy
Search strategies were developed using systematic automated and manual searches. First, we conducted a comprehensive automated search of five electronic bibliographic databases-including MEDLINE via PubMed, Cochrane CENTRAL, AIDSLINE, AMED, CINAHL, TOXNET, SciELO, and ISI-Web of Science were searched from 1996 to February 29, 2008; except for AIDSLINE, which was searched from 1996 up to 2000, when the inclusion of new citations was discontinued. This search combined standardized search terms (keywords and medical subject heading terms) that reflect key domains: (a) HIV/AIDS, (b) compliance (i.e., adherence, compliance, directly observed therapy), (c) addiction (i.e., substance abuse, substance dependence), and (d) target population (i.e., PLWHA). Citations that intersect all four domains were downloaded into the study database.
To reduce publication bias and gaps in the automated search, we implemented four supplementary search strategies to identify additional studies. First, we searched the published conference abstracts from HIV/AIDS and STD conferences using the same domains as the automated search. Second we searched the National Institutes of Health's Computer Retrieval of Information on Scientific Projects (CRISP) database (http://crisp.cit.nih.gov) to identify researchers working in the field of HIV/AIDS and/ or drug addiction. Third, we contacted authors of selected papers to obtain upcoming publications. Finally, we reviewed the reference lists of all selected studies for additional citations. All studies identified through these procedures that met our eligible criteria were entered into the study database.
To be included in the review, studies had to evaluate adherence to HAART as the primary outcome, report a given cut-off to define optimal adherence (e.g., 90 or 95%), include multivariable analyses to assess correlates of adherence and present data stratifying participants according to history of drug use (drug users vs. never drug users), or evaluate only current/former drug users on their studies. Further details are available elsewhere (Malta et al. 2008) . Studies with an outcome defined as continuous were included in the systematic review (Malta et al. 2008) , but not in the meta-analysis, due to methodological constraints associated with combining studies using continuous and discrete outcomes.
Study Selection and Data Extraction
Using a predefined protocol, two investigators (MM, FIB) extracted data from peer-reviewed papers addressing adherence among HIV-positive DU and independently assessed their eligibility. Using standardized coding forms, each selected paper was coded for study characteristics (study date, location, study design [RCT, cross-sectional, or When more than one adherence measurement was used (e.g., MEMs and patient's self-report), data from all methods were collected, and an average adherence estimate was calculated, using information collected with the different methods. The adherence estimate included in our analysis referred to the percentage of patients rated as adherent, according to the cut-off and adherence measurement method adopted by each study. After potentially relevant studies were identified and data abstracted, the two investigators met to achieve consensus regarding eligibility.
Statistical Analysis
Standard meta-analytic methods were used (Cooper and Hedges 1994; Lipsey and Wilson 2001) . A random-effects model for aggregating individual effect sizes was used, because it provides a more conservative estimate than a fixed-effects model of variance. This approach generates more accurate inferences since it recognizes studies as a sample of all potential studies and incorporates betweenstudy variability on the overall pooled estimation (Hedges and Vevea 1998; van Houwelingen et al. 2002) . Thresholds for adherence were considered as greater than or equal to the cutoff levels used on each study, and the raw proportion of DUs recorded as optimally adherent by each study was used to pool the overall proportion, using the DerSimonian-Laird random-effects method (Fleiss 1993; DerSimonian and Laird 1986) .
The I 2 index was calculated as a measure of the overall variation in adherence proportion that was attributable to between-study heterogeneity (Higgins and Thompson 2002; Higgins et al. 2003) . Higgins and Thompson (2002) proposed a tentative classification of I 2 values with the purpose of helping to interpret its magnitude. Thus, percentages of around 25% (I 2 B 25), 50% (I 2 = 50), and 75% (I 2 C 75) were interpreted as low, medium, and high heterogeneity, respectively. According to a recent review (Huedo-Medina et al. 2006) , the I 2 index assesses not only heterogeneity in a meta-analysis but also the extent of that heterogeneity. It is considered a more appropriate procedure than the Q test in assessing whether there is true heterogeneity among the studies in a meta-analysis (Higgins et al. 2003) . Experts have demonstrated that the I 2 index exhibits higher power with a larger number of studies ([20) with an average sample size higher than 80 individuals (Huedo-Medina et al. 2006) .
We anticipated large between-study heterogeneity (I 2 C 75) considering the varied populations, the different definitions of 'optimal' adherence, and time frames used in the assessment of adherence. According to standard metaanalysis guidelines, when observational studies are pooled, heterogeneity of populations (e.g., US vs. international studies), design (e.g., case-control vs. cohort studies), and outcome (e.g., different studies yielding different relative risks that cannot be accounted for by sampling variation) is expected (Berlin 1995; Stroup et al. 2000) .
Researchers have used a variety of time frames to capture adherence estimates, ranging from the previous day to previous year. The widely used AIDS Clinical Trials Group (ACTG) adherence instrument employs a 4-day time frame (Chesney et al. 2000) . Shorter time frames have generally been considered to provide more accurate recall; however, a recent study suggested that 1 month time frame may be more accurate than 3-or 7-day periods (Lu et al. 2008) . In an attempt to further contribute to this discussion, we aggregated studies according to their time frames into three subgroups: 1-14 days, 2 weeks to 6 months, and 1-2.5 years (no selected study used a time frame between 6 months and 1 year).
One forest plot was drawn for all 38 studies and additional figures were created according to those time frames. Forest plots illustrate the proportion of DUs recorded as optimally adherent by each study, its 95% confidence intervals (CI) and the overall DerSimonian-Laird pooled estimate.
A mixed-effects meta-regression model was used to specifically assess the underlying reasons for betweenstudy heterogeneity, whereby the proportion of DUs recorded as optimally adherent by each study was transformed to their logit value. The logit transformation (logistic function) allows for calculation because the values are approximately normally distributed in contrast with probability scores, which range from 0 to 1 (Viechtbauer 2007) .
Results from univariate analyses with P-values B0.20 were included in the multivariable analysis. The following covariates were included in the meta-regression multivariable model: time frame (according to the three categories indicated above), most frequently abused drug in the study sample (heroin, crack/cocaine, heroin and crack/cocaine, and abstinence), method of assessment for adherence (selfreport, pharmacy records, MEMS), and adherence cut-off ([80%). Analyses were conducted using Stata version 10.0 (StataCorp, College Station, Tex) and R version 2.6.2 (R Core Development Core Team 2004). Graphics were generated using StatsDirect version 2.5.2 (StatsDirect Ltd, Cheshire, England).
Results

Study Characteristics
Thirty-eight studies meeting inclusion/exclusion criteria were identified (Fig. 1 ). Approximately half assessed adherence using patient self-reports, while the remainder used a broad range of measurements (e.g., pharmacy records, MEMS, secondary data). Studies used heterogeneous cut-offs to define optimal adherence (range: 75-100%). The 38 studies enrolled a total of 14,960 patients (range: 40-5,073; median 164). The 23 studies which used self-reported adherence enrolled a total of 5,150 patients (range: 42-636; median: 164), while 11 studies which evaluated adherence through pharmacy records and/or pill counts enrolled a total of 9,480 patients (range: 85-5,073; median: 234). The four studies which evaluated adherence using MEMS or a combination of self-report and clinical data enrolled a total of 330 patients (range: 40-150; median: 70). We were unable to identify any studies meeting our eligibility criteria that were conducted in developing countries (Table 1) .
Eleven studies defined optimal antiretroviral adherence as 100% uptake of the prescribed doses (Crisp et al. 2004; Haug et al. 2005; Martin et al. 2005; Palepu et al. 2003a Palepu et al. , b, 2004b Pradier et al. 2001; Purcell et al. 2004; Sharpe et al. 2004; Waldrop-Valverde and Valverde 2005; WaldropValverde et al. 2006) . Eight studies assessed optimal adherence as greater than 95% (Escobar et al. 2003; Kerr et al. 2004; Knowlton et al. 2006; Palepu et al. 2004b Palepu et al. , 2006 Turner et al. 2003; Wood et al. 2003b Wood et al. , 2004b . Three studies used adherence greater than 90% (Arnsten et al. 2007; Gordillo et al. 1999; Hinkin et al. 2007 ); eight as greater than 80% (Altice et al. 2001; Avants et al. 2001; Bouhnik et al. 2002 Bouhnik et al. , 2005 Carrieri et al. 2003a; Clarke et al. 2003; Duran et al. 2001; Moatti et al. 2000) ; and one study as greater than 75% of prescribed medicines (Altice et al. 2004 ). One study used two different cut-offs-90 and 100% (Liu et al. 2006) .
Six studies used a combination of adherence measurements, e.g., self-report and MEMS (Crystal et al. 2001; Kerr et al. 2005; Lucas et al. 2001; Martini et al. 2004; McNabb et al. 2001; Roca et al. 1999 ).
Meta-Analysis
The combined pooled adherence across 38 studies (N = 14,960 was 0.60 (95% CI: 0.52-0.68, Fig. 2 ), indicating that the pooled proportion of DUs recorded as optimally adherent by all studies was 0.60. Due to the large between-study heterogeneity (I 2 = 98.8%), we conducted subgroup analyses, re-calculating the pooled adherence according to their time frames: studies with a time frame B2 weeks 17 studies (N = 3,795) between 2 weeks and 6 months 10 studies (N = 3,071) and studies with time frames between 1 year and 2.5 years (11 studies, N = 8,094). The pooled estimate for the shortest period was higher (0.71; 95% CI: 0.68-0.74, I 2 = 69.7%; Fig. 3a ) than the pooled estimated for the intermediate period (0.54, 95% CI: 0.49-0.59, I 2 = 80.8%, Fig. 3b ). The group using a time frame greater than 1 year had the lowest pooled Fig. 3c) .
A meta-regression model (Table 2 ) was fitted to evaluate major predictors of the between-studies heterogeneity, including the following covariates: time frame; substance used; type of adherence measurement, adherence cut-off and payment for receiving HAART. After adjustment, only the time frame remained associated with the between-study heterogeneity (P-value B0.05). Compared to studies using the shorter time frame (B2 weeks), studies using a larger time frame had adherence estimates approximately 50% lower. For studies using a time frame between 2 weeks and 6 months, the adjusted odds ratio (AOR) was 0.47 (95% CI: 0.25-0.88), while for studies using a time frame higher than 1 year, AOR was 0.44 (95% CI: 0.23-0.84).
Treatment Outcomes
Eighteen of the 38 studies evaluated HAART-related clinical outcomes (Avants et al. 2001; Bouhnik et al. 2005; Carrieri et al. 2003a; Duran et al. 2001; Knowlton et al. 2006; Lucas et al. 2001; McNabb et al. 2001; Moatti et al. 2000; Palepu et al. 2003a Palepu et al. , b, 2004a Palepu et al. , b, 2006 Pradier et al. 2001; Roca et al. 1999; Waldrop-Valverde et al. 2006; Wood et al. 2003a Wood et al. , 2004b (Table 3) .
Active drug use was identified by some authors as a barrier against better clinical outcomes (Lucas et al. 2001; Palepu et al. 2003a, b; Wood et al. 2004b) . In these studies, active drug use (especially cocaine use) was identified as a stronger predictor of poor adherence and, in turn, failure to achieve/maintain better clinical outcomes over time. A study conducted in Baltimore, US, reported that active drug use was strongly associated with underutilization of HA-ART, non-adherence, and poorer responses to therapy; former drug users and non-drug users had comparable outcomes (Lucas et al. 2001) .
Substitution therapy for opiate dependence was independently associated with HIV-1 RNA suppression according to several studies (Avants et al. 2001; Duran et al. 2001; Lucas et al. 2001; Moatti et al. 2000; Palepu et al. 2006) . In a study by Palepu et al. (2006) in Vancouver, Canada, methadone maintenance therapy (MMT) Psychiatric conditions, particularly depression, were found to be associated with poorer response to HAART. Bouhnik et al. (2005) found that besides non-adherence, having a higher level of depressive symptoms following HAART initiation was highly associated with HIV clinical progression (HR: 5.3; 95% CI: 2.2-13.0; P \ 10 -3 ). In some studies, indicators of low socioeconomic status were also associated with poorer clinical and virologic response among HIV-positive DU receiving HAART. Fig. 2 Pooled proportion of all HIV ? DU adhering to antiretroviral therapy. Note: The combined data marker indicates the DerSimmonian-Laird combined proportion Fig. 3 a Pooled proportion of all HIV ? DU adhering to ART, studies using 2 weeks or less for adherence recall. b Pooled proportion of all HIV ? DU adhering to ART, studies using 16 days to 6 months for adherence recall. c Pooled proportion of all HIV ? DU adhering to ART, studies using more than 6 months of adherence recall. Note: The combined data marker indicates the DerSimmonian-Laird combined proportion These studies identified access to social support and stable housing as key aspects to achieve/maintain both HAART adherence and viral suppression (Avants et al. 2001; Carrieri et al. 2003a; Knowlton et al. 2006; Lucas et al. 2001; Palepu et al. 2003a Palepu et al. , b, 2004a Palepu et al. , b, 2006 Wood et al. 2003b) .
Characteristics directly related to the class of antiretroviral drugs (two nucleosides ? protease inhibitor vs. nonnucleoside reverse transcriptase inhibitors), time on HA-ART (more experienced vs. less experienced patients), and levels of viral load/CD4 cells counts at the time of HAART initiation were also identified as cofactors independently associated with viral suppression and immune reconstitution (Knowlton et al. 2006; Palepu et al. 2003a Palepu et al. , b, 2004a Palepu et al. , 2006 .
Discussion
Findings from this meta-analysis suggest that adherence to HAART among HIV-positive drug users falls within the range observed among PLWHA in general, which is approximately 60%. However, the strong heterogeneity among different studies jeopardizes efforts to standardize the assessment of adherence and to derive evidence-based guidelines about how adherence should be measured and how existing measures can be improved.
A recent meta-analysis evaluating 31 studies measuring adherence to HAART among adult PLWHA from North America (N = 17,573) reported a pooled estimate of 55% (95% CI: 49-62%), slightly lower than that identified by our study, but with overlapping confidence intervals (Mills et al. 2006) . Non-adherence to HAART in adult populations has ranged from 33 to 88%, depending on the methods by which adherence is defined and evaluated (Friedland and Williams 1999) .
A recent paper by Bangsberg (2006) found that viral suppression and better clinical outcomes was common among patients with a 54-100% mean adherence level, if the patient was using non-nucleoside reverse-transcriptaseinhibitor regimens instead of unboosted protease inhibitor regimens which are known to be partially suppressive. Although perfect adherence is an important goal, viral suppression and better clinical outcomes are possible with moderate adherence to potent regimens, such as those levels identified by our study. Our systematic review (Malta et al. 2008 ) and meta-analysis favor the conclusion that drug users may achieve good adherence levels and clinical outcomes if given access to HAART; outcomes are improved when HAART is offered in the context of social supports and methadone maintenance treatment (Clarke et al. 2003; Malta et al. 2008; Moatti et al. 2000; Palepu et al. 2006) .
Evidence-based studies on barriers and facilitators to adherence among HIV-positive DU have been scarce, particularly in developing countries. This is of concern given that the largest HIV epidemics among DU are now taking place in developing/transitional countries, such as eastern Europe, as well as south east, south and central Asia (Mathers et al. 2008) . Over the coming decades, PLWHA from developing countries will constitute a growing proportion of the World's HAART recipients as treatment roll-out progresses. Studies on HAART utilization and adherence in low and middle income countries are urgently needed in order to inform efforts to implement and expand HAART use in regions where it is needed the most.
Our meta-analysis found that studies using shorter time frames yielded more homogeneous estimates of adherence among HIV-positive DUs. A recent report comparing selfreported and MEMS adherence among HIV-positive patients found less overestimation of self-reported adherence with a 1 month time frame than with 3-or 7-day time frames among participants with higher socioeconomic status-94% had finished high school (Lu et al. 2008) . There is no consensus about the more accurate measurement of HAART adherence among HIV-positive patients (Chesney 2006; Pearson et al. 2007a, b; Simoni et al. 2007) . Clinical guidelines for the management of HIV- Time on HAART (AOR 1.08; 95% CI 1.02-1.14)
Factors associated with CD4 cell count rise:
MMT (AOR 1.58; 95% CI 1.26-1.99), C95% HAART adherence (AOR 1.42; 95% CI 1.13-1.78)
Baseline CD4 cell count (AOR 1.27; 95% CI 1.18-1.36)
IDU d C 95% adherents to HAART versus IDU \ 95% adherents to HAART (previous day adherence):
Lower mean HIV RNA log-transformed copies (ml): 8.7 (±2.5) versus 10.0 (±2.16); P = 0.047 No differences in mean CD4 log-transformed cell counts (mm Patients with history of injection drug use had lower CD4 response rates (log-rank: P \ 0.05)
Among patients with adherence C95%, no statistical difference was found between IDU and Never-IDU (log-rank: P = 0.349) Adherence (AOR 1.27; 95% CI 1.06-1.51); lower baseline HIV-1 RNA (AOR 1.30; 95% CI 1.01-1.66); highly active antiretroviral therapy (AOR 4.10; 95% CI 1.56-10.6); months on therapy (AOR 1.1; 95% CI 1.06-1.14) Carrieri et al. (2003a) Undetectable HIV viral load, IDU adherents versus IDU non-adherents (\500 copies/ml):
56.8% versus 36.3% (P = 0.09) Duran et al. (2001) Median viral load, last visit:
Non-adherent 3.80 log 10 copies/ml, IQR: 2.60-5.04
Adherents patients: 2.30 log 10 copies/ml, IQR: 2.30-3.64
Strictly adherent: 2.30 log 10 copies/ml, IQR: 2. Active drug users 0.8 log 10 copies/ml versus 1.7 in nonusers and 1.6 in former users (P \ 0.001, both comparisons) Median CD4 ± lymphocyte count increase:
Active drug users 65 cells/mm 3 versus 116 in nonusers and 122 in former users (P = 0.003 both comparisons)
Prevalence of patients achieving undetectable HIV viral load (B400 copies/ml):
32% of active drug users versus 46% of nonusers versus 44% of former users (P = 0.02 both comparisons)
AIDS Behav (2010) 14:731-747 741 positive drug users favor the use of shorter time frames to evaluate their adherence to HAART, following, for instance, the widely used ACTG adherence instrument that employs a 4-day time frame (Chesney et al. 2000; New York State Department of Health 2005) . However, it was not possible to disentangle the specific influence of different time frames and the underlying conceptual strategies to assess adherence used by clinical trial groups.
Measuring long-term adherence is particularly challenging, since adherence often fluctuates (Carrieri et al. 2003b) and may decrease over time (Howard et al. 2002; Parruti et al. 2006; Pearson et al. 2007a, b; Pinheiro et al. 2002) . According to a study conducted by the HIV Epidemiology Research Study (HERS) with HIV-positive drug users, participants' adherence declined from 64% at 1 month to 45% at 6 months after initiation of HAART Moatti et al. (2000) Median viral load, non-adherent versus adherents patients: 3.9 log 10 copies/ml versus 2.7 log 10 copies/ml (P = 0.008)
Median decrease in viral load before and after HAART initiation, non-adherent versus adherents patients:
-0.53 log 10 copies/ml versus -1.04 log 10 copies/ml (P = 0.025)
Percentage of patients with undetectable viral load or with a viral load decrease higher than 1 log 10 , non-adherent versus adherents patients:
40.3% versus 57.0% (P = 0.04)
Median increase of CD4 cell counts among non-adherent versus adherents patients: (Arnsten et al. 2001) . Nevertheless, Parruti et al. (2006) found that adherence remained fairly stable up to 24 months of follow-up, declining about 5% every 6 months thereafter. Therefore, the differences observed in our analyses relating to short versus long-term adherence may represent a true decrease in adherence over time.
Further studies are needed to clarify this issue. Most studies reporting higher adherence were conducted among DU receiving HAART in structured settings, particularly those offering both addiction treatment and psychosocial support (Purcell et al. 2004 ) and/or directly observed therapy (Altice et al. 2004; Smith-Rohrberg et al. 2006) . In particular, DU engaged in opioid substitution therapy significantly reduced their drug using habits, have better adherence to HAART, and usually achieved the expected HIV-1 RNA suppression and CD4 cell count response to HAART (Clarke et al. 2003; Moatti et al. 2000; Palepu et al. 2006) . These findings suggest that the extent to which one's daily life is routinized and stabilized may improve adherence and, as a consequence, responses to HIV treatment among DU.
Although opioid substitution therapy may be associated with better HAART adherence among people who use heroin and other opioids, illicit stimulant use remains a key problem. HIV-positive active cocaine users may seek treatment with considerable delay, initiating HAART in more advanced disease stages (Cofrancesco et al. 2008; Martín-Sánchez et al. 2002) , which, in turn, decreases its effectiveness. Methamphetamine use may also represent similar challenges (Hinkin et al. 2007 ) but no studies of HAART adherence among exclusively methamphetamine users met our study's eligibility criteria. Active alcohol abuse (Palepu et al. 2003a, b) is also associated with lower adherence to HAART. Patients co-infected with HCV and other STIs may also have worse clinical outcomes (Miller et al. 2005; Vissoci Reiche et al. 2008) .
We identified a high degree of between-study heterogeneity in adherence estimates, since selected studies used a wide range of cut-offs to define optimal adherence (range: 75-100%), assessed adherence through different measurements, used different time frames, and collected data in a variety of research centers and clinical settings. Due to this high degree of heterogeneity, which was not completely explained either by sub-groups analysis or by meta-regression, our pooled results need to be viewed with caution. The exclusion criteria for our analysis may have limited the generalizability of our findings. A recent metaanalysis evaluating HAART adherence among PLWHA comprising a majority of observational studies and a few randomized controlled trials revealed a high heterogeneity with an I 2 of 98.4% (Mills et al. 2006) . Heterogeneity between studies is a key issue for further studies and should be the object of concerted efforts toward standardization. Multicenter studies and especially cross-cultural studies are sorely needed.
This meta-analysis has other limitations. We aimed to reduce reviewer bias by conducting abstraction independently, in parallel. We cannot, however, know to what extent reporting bias may have influenced our conclusions. Reporting bias, particularly in studies relying only on selfreport may have limited our ability to accurately identify the actual levels of adherence to HAART among HIV-positive DU. The accuracy of such reports cannot be verified in the context of the current study. However, in the context of our analysis, differential biases were not made evident by meta-regression.
We were unable to identify studies conducted in developing countries, making it impossible to generalize our findings to those settings. Our review relies on information reported in peer-reviewed scientific publications of studies conducted in developed countries, which did not represent those DU living in specific contexts, such as eastern Europe, where the AIDS epidemic is mainly driven by drug using population and access to HAART is uneven (WHO/UNAIDS 2007).
While there is significant reluctance among medical care providers to deliver HAART to DU, the evidence supporting this decision is limited (Aceijas et al. 2006; Malta et al. 2008; Vlahov and Celentano 2006) . Overcoming stigma and discrimination towards HIV-positive DU, and improving the quality and efficacy of HIV care and management is necessary to achieve optimal clinical outcomes for this marginalized population. Much has to be done in terms of a comprehensive monitoring of adherence, including the standardization of methods, time frames and the very covariates to be explored as predictors and/or confounders. Our meta-analysis suggests that HIV-infected DUs can achieve comparable adherence levels to non-drug using populations, and argues strongly against discriminatory polices that prevent DUs from accessing HAART.
